Cadwell

Wuhan Cadwell Biotechnology Co., Ltd. is centered on the team of Ma Ding, an academician of the Chinese Academy of Engineering, with Wuhan Cadwell Biotechnology Co., Ltd. as the lead unit, integrating Hubei Province's first-class scientific research platforms (the Key Laboratory of Carcinogenesis and Invasive Cancer of the Ministry of Education and the State Key Laboratory of Virology), and has acquired 30 mu of land in Optics Valley Biolake to build the "Gynecological Oncology Diagnosis and Treatment Innovation Achievement Transformation Center Project," committed to building a first-class, internationally leading gynecological oncology diagnosis and treatment innovation product R&D center and supporting production base.
Wuhan Cadwell Biotechnology Co., Ltd. was established in February 2018 with a registered capital of 10 million yuan, and is currently in the R&D and optimization stage of an NGS-based HPV capture kit. To supplement the project's R&D strength, by shareholder decision, in August 2018, 6.65 million yuan was invested to establish a holding subsidiary, Wuhan Cadgene Biotechnology Co., Ltd., for conducting preclinical experiments of a next-generation sequencing-based HPV typing and integration detection kit; in November 2018, a wholly-owned subsidiary, Wuhan Cadwell Medical Laboratory Co., Ltd., was established, focusing on the research and application of high-end medical testing technologies, mainly next-generation sequencing (NGS) supplemented by other special tests, in the field of gynecological oncology diagnosis and treatment.